Clvr Hlth Inv-A (CLOV)
$3.25
0.08 (2.46%)
CLOV Stock Quote Delayed 30 Minutes
The Two Faces of Clover Health
CTO Andrew Toy has a great tool in the Clover Assistant, which can cut the costs of treating chronic conditions among aging patients. But will he get a chance to deploy it?
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$3.51
Market Cap
1.70B
PE Ratio
-37.02
EPS
-0.0878
Volume (Avg. Vol.)
7.00M
Day's Range
$3.22 - $3.48
52-Week Range
$0.61 - $4.87
Dividend & Yield
N/A (N/A)
CLOV Stock Predictions, Articles, and Clvr Hlth Inv-A News
Clover Health: 3 Key Factors That Are Worrisome and 1 That Brings Hope
CLOV stock has underperformed in 2021, became a meme stock, and now has many risks and challenges to face to reach profitability.
As Clover Health Stock Gets Diluted, Stockholders Are Giving Up
CLOV stock continues to punish long-suffering shareholders as it losses value. The latest public offering at the low-ball price of $5.75 is another nail in the coffin.
Clover Health Is Now a Penny Stock, Denoting Its Serious Decline
CLOV stock is saddled with issues that include a declining share price and operational issues that are only getting more troublesome.
MEME ETF: The Top 10 Holdings of the New Roundhill Fund for Meme Stock Investors
The new Roundhill MEME ETF (MEME) is live and with it comes an opportunity to invest in a wide variety of meme stocks it holds.
With Hope and Hype Gone, Clover Health Will Now Remain a Penny Stock
Likely to languish at or below $5 per share for a while, skip out for now with CLOV stock.
If November Is Any Indication, Clover Health Is on Life Support
November was brutal for shareholders of Clover Health. CLOV stock lost close to 40% of its value. Trading under $5, it’s tough to recommend.
The Engine Boosting Clover Health Stock is a CTO Working to Disrupt Medicare
The Clover Assistant is meant to align incentives between health care providers and managed care companies, which could cut costs and create profits. That's what CLOV stock investors should focus on.
The Clover Health Dilemma: Is it a Good Buy or Goodbye?
Last rites for Clover Health Investments seem premature, but CLOV stock is being challenged off and on the price chart.
Clover Health Is Expanding, But Its Path to Profitability Is Unclear
Clover provides a relevant solution and is expanding, but its cash flow makes CLOV stock an unattractive pick at this point.
CLOV Stock: The Chamath Palihapitiya Tweet Giving Clover Health a Lift Today
Clover Health Investments (CLOV) stock is getting a boost on Friday thanks to a couple of Tweets from Chamath Palihapitiya.
CLOV Stock Alert: There’s a $300M Reason Clover Health Is Stumbling Today
Meme stock favorite Clover Health is under pressure today after announcing a new secondary stock offering that has upset investors.
Revenue Growth Makes Clover Health Stock a Strong Buy
A combination of triple-digit growth, expanding provider networks and a low share price make CLOV stock hard to resist.
Could Clover Be Starting to Make a Comeback?
Clover Health's poor insurance underwriting performance dragged down CLOV stock. However, the company may be making progress.
What Investors Should Remember About Clover Health
There is no question Clover Health remains a risky proposition. However, there is one thing about CLOV stock that could make a difference.
Clover Health Has Long Term Potential with Short Term Volatility
CLOV stock has a legitimate bullish thesis to play out well over time. Meanwhile, investors have to stomach the short term shenanigans.
